CPT Code Anticipated For AMD Combination Therapy Using Lasers, QLT Says
This article was originally published in The Gray Sheet
Executive Summary
A combination drug/device therapy for "wet" age-related macular degeneration (AMD) will likely have a current procedural terminology (CPT) payment code in effect by Jan. 1. The treatment uses QLT PhotoTherapeutics' injectable drug Visudyne (verteporfin) activated by lasers manufactured by Coherent Medical (Opal Photoactivator) and Zeiss Humphrey Systems (Visulas 690).